Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 12

1.

A comparative study of CSF neurofilament light and heavy chain protein in MS.

Kuhle J, Plattner K, Bestwick JP, Lindberg RL, Ramagopalan SV, Norgren N, Nissim A, Malaspina A, Leppert D, Giovannoni G, Kappos L.

Mult Scler. 2013 Oct;19(12):1597-603. doi: 10.1177/1352458513482374. Epub 2013 Mar 25.

PMID:
23529999
2.

Neurofilaments as biomarkers in multiple sclerosis.

Teunissen CE, Khalil M.

Mult Scler. 2012 May;18(5):552-6. doi: 10.1177/1352458512443092. Epub 2012 Apr 4. Review.

PMID:
22492131
3.

A systematic review and meta-analysis of CSF neurofilament protein levels as biomarkers in dementia.

Petzold A, Keir G, Warren J, Fox N, Rossor MN.

Neurodegener Dis. 2007;4(2-3):185-94. Review.

PMID:
17596713
4.

Multiple sclerosis cerebrospinal fluid biomarkers.

Giovannoni G.

Dis Markers. 2006;22(4):187-96. Review.

5.

Axonal degeneration in multiple sclerosis: can we predict and prevent permanent disability?

Lee JY, Taghian K, Petratos S.

Acta Neuropathol Commun. 2014 Aug 27;2:97. doi: 10.1186/s40478-014-0097-7. Review.

6.

Biological markers in CSF and blood for axonal degeneration in multiple sclerosis.

Teunissen CE, Dijkstra C, Polman C.

Lancet Neurol. 2005 Jan;4(1):32-41. Review.

PMID:
15620855
7.

Clinical, MRI, and CSF markers of disability progression in multiple sclerosis.

Gajofatto A, Calabrese M, Benedetti MD, Monaco S.

Dis Markers. 2013;35(6):687-99. doi: 10.1155/2013/484959. Epub 2013 Nov 10. Review.

8.

Developing Biomarkers for MS.

Gnanapavan S, Giovannoni G.

Curr Top Behav Neurosci. 2015;26:179-94. doi: 10.1007/7854_2014_362. Review.

PMID:
25502545
9.

Biomarkers of therapeutic response in multiple sclerosis: current status.

Harris VK, Sadiq SA.

Mol Diagn Ther. 2014 Dec;18(6):605-17. doi: 10.1007/s40291-014-0117-0. Review.

10.

Cerebrospinal fluid proteomics in multiple sclerosis.

Kroksveen AC, Opsahl JA, Guldbrandsen A, Myhr KM, Oveland E, Torkildsen Ø, Berven FS.

Biochim Biophys Acta. 2015 Jul;1854(7):746-56. doi: 10.1016/j.bbapap.2014.12.013. Epub 2014 Dec 16. Review.

PMID:
25526888
11.

Emerging molecular biomarker targets for amyotrophic lateral sclerosis.

Costa J, de Carvalho M.

Clin Chim Acta. 2016 Apr 1;455:7-14. doi: 10.1016/j.cca.2016.01.011. Epub 2016 Jan 14. Review.

PMID:
26774696
12.

The Use and Potential of pNF-H as a General Blood Biomarker of Axonal Loss: An Immediate Application for CNS Injury.

Shaw G.

In: Kobeissy FH, editor. Brain Neurotrauma: Molecular, Neuropsychological, and Rehabilitation Aspects. Boca Raton (FL): CRC Press/Taylor & Francis; 2015. Chapter 21.

Items per page

Supplemental Content

Write to the Help Desk